Advertisement

Oncology / Hematology General

Prostate Cancer Patient Lymph Node Staging Optimization

Sep 16, 2022

There were currently no established standards for quantitatively assessing 68Ga-PSMA-PET/CT results for diagnosing lymph node metastases in prostate cancer patients. Hematological indicators associate...

P35-1 ED in Metastatic PC Patients Treated with ADT

Sep 16, 2022

Treatment for both localized and metastatic prostate cancer (PC) affects sexual function. In localized PC, erectile dysfunction (ED) has been researched, but seldom in advanced or metastatic PC. For a...

MO24-6 mHSPC Incidence, Mortality, and Clinical Characteristics

Sep 16, 2022

The incidence and fatality rates for prostate cancer vary substantially between Asians and Westerners. There was no information available on the precise prevalence of mHSPC in Thailand. In the Thai co...

MO20-3 CAPE: Enzalutamide or Abiraterone Drug Resistance in PCa Cells

Sep 16, 2022

In order to treat metastatic castration-resistant prostate cancer (mCRPC), 2 medications that target the androgen receptor axis are Enzalutamide (ENZ) and Abiraterone acetate (AA). But the majority of...

26P Uterine Sarcoma: A Retrospective Study

Sep 16, 2022

Less than 3% of gynecologic malignancies and 3 to 7% of uterine malignancies are uterine sarcomas (US), which are uncommon tumors. The US is known for its aggressive nature and high risk of local and ...

High-grade B-cell Lymphoma, NOS, Diagnosis and Treatment

Sep 15, 2022

A recently developed diagnostic category for aggressive B-cell lymphomas is high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS). It contains tumors that lack double-hit cytogenetics and e...

A Primary Lymphoma of the Central Nervous System

Sep 15, 2022

With no indication of systemic involvement, primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous cancer that affects the brain, spinal cord, leptomeninges, or vitreoretina...

The Use of Sutimlimab in Cold Agglutinin Disease Patients

Sep 15, 2022

Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody, quickly stopped hemolysis in the single-arm CARDINAL trial in recently transfused patients with cold agglutinin dis...

Hematopoietic Stem Cells Self-Renew with PLAG1 Dampening Protein Synthesis

Sep 15, 2022

Dormancy in hematopoietic stem cells (HSCs) is known to maintain HSC function and long-term integrity. Although it was acknowledged that regulating stress responses brought on by HSC activation is cru...

Etoposide and ASCT Effects On Survival in PTCL Patients Aged 65 Years and Older

Sep 15, 2022

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) are used to treat peripheral T-cell lymphoma (PTCL) in patients of age less than 65. Although consolidation with autologous stem cell ...

External Beam Radiation Therapy in Patients with Stage IIIC Uterine Endometrioid Carcinoma

Sep 15, 2022

Determine if patients with stage IIIC endometrioid endometrial cancer who receive external beam radiation (EBRT) in addition to adjuvant chemotherapy with or without vaginal brachytherapy have a great...

Incidence of Recurrent Acute Myeloid Leukemia: A Sensitive and Repeatable Method

Sep 12, 2022

For a study, researchers sought to understand the relevant cell lineages, aberrant differentiation/maturation patterns, and the expression of aberrant antigens in acute myeloid leukemia (AML), multipa...

Cytarabine/Idarubicin Reinduction in COVID-19 Infected Patients with Refractory Acute Myeloid Leukemia

Sep 12, 2022

Myelosuppressive chemotherapy can cause major infectious problems in individuals with aggressive malignant hematologic diseases, which can worsen by an active COVID-19 infection. For a study, research...

In Pediatric Patients with Acute Myeloid Leukemia, A Seven-Gene Signature Predicting Prognosis Is Identified

Sep 12, 2022

For a study, researchers sought to create a pyroptosis-related risk score (RS) model for acute myeloid leukemia prognosis (AML). The TARGET (training) and E-MTAB-1216 (validation) datasets were dow...

Acute Myeloid Leukemia with FLT3 Mutations: Venetoclax Plus Gilteritinib

Sep 12, 2022

The standard treatment for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) is the FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib, although this drug seldom lowers ...

TP53-mutant Acute Myeloid Leukemia and Myelodysplastic Syndrome Treated with Eprenetapopt Plus Azacitidine

Sep 12, 2022

Even after an allogeneic hematopoietic stem cell transplant (HCT), outcomes in TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remain dismal. A first-in-class smal...

Decline in Prostate-specific Antigen Levels Identifies Survivors Scheduled for PSMA-directed RLT

Sep 07, 2022

For patients with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly being included in the treatment ...

Prostate Cancer (PCa): Long-Term Disease Progression

Sep 07, 2022

There aren't many long-term population-based cohort studies of males with prostate cancer. However, negative effects might persist for a long time after therapy. For a study, researchers sought to eva...

BAT PSA Provocation: Response to First-line Androgen Deprivation

Sep 07, 2022

The Phase II BATMAN trial (Bipolar Androgen Therapy for Men with Androgen-ablation Nave Prostate Cancer) were previously published. For a study, researchers sought to assess the safety and effectivene...

Circulating microRNA Profiling for Oncological Outcomes Prediction in PCa Patients After RP

Sep 07, 2022

Despite the fact that radical prostatectomy is linked to favorable long-term oncological outcomes, about 30% of patients experience biochemical recurrence, necessitating salvage therapies. Therefore, ...